IL147885A0 - Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity - Google Patents

Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Info

Publication number
IL147885A0
IL147885A0 IL14788500A IL14788500A IL147885A0 IL 147885 A0 IL147885 A0 IL 147885A0 IL 14788500 A IL14788500 A IL 14788500A IL 14788500 A IL14788500 A IL 14788500A IL 147885 A0 IL147885 A0 IL 147885A0
Authority
IL
Israel
Prior art keywords
pyridazines
fused
inhibiting activity
substituted
angiogenesis inhibiting
Prior art date
Application number
IL14788500A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL147885A0 publication Critical patent/IL147885A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL14788500A 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity IL147885A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10
PCT/US2000/021579 WO2001010859A1 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Publications (1)

Publication Number Publication Date
IL147885A0 true IL147885A0 (en) 2002-08-14

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14788500A IL147885A0 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Country Status (19)

Country Link
EP (1) EP1208096B1 (enExample)
JP (1) JP2003506447A (enExample)
KR (1) KR20020019969A (enExample)
CN (1) CN1378543A (enExample)
AR (1) AR025068A1 (enExample)
AT (1) ATE265448T1 (enExample)
AU (1) AU775237B2 (enExample)
BR (1) BR0013113A (enExample)
CA (1) CA2381621A1 (enExample)
CO (1) CO5180637A1 (enExample)
DE (1) DE60010280T2 (enExample)
ES (1) ES2219382T3 (enExample)
IL (1) IL147885A0 (enExample)
MX (1) MXPA02001324A (enExample)
NO (1) NO20020569L (enExample)
NZ (1) NZ517087A (enExample)
PE (1) PE20010494A1 (enExample)
WO (1) WO2001010859A1 (enExample)
ZA (1) ZA200200691B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CN100372535C (zh) * 2002-09-24 2008-03-05 诺瓦提斯公司 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
AU2003288034A1 (en) * 2002-11-12 2004-06-03 Novartis Ag Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
PL2167549T3 (pl) 2007-06-19 2013-03-29 Rynel Inc Materiały zawierające cząstki polimeru rozpuszczalnego w wodzie oraz sposoby ich wytwarzania i stosowania
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
CA2732101C (en) * 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CN117355303A (zh) * 2021-01-28 2024-01-05 佛罗里达大学研究基金会公司 化合物及其用于治疗神经退行性、退行性和代谢病症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
EP0722936B1 (en) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen

Also Published As

Publication number Publication date
AU775237B2 (en) 2004-07-22
ES2219382T3 (es) 2004-12-01
NO20020569L (no) 2002-04-10
DE60010280D1 (de) 2004-06-03
MXPA02001324A (es) 2002-07-22
CO5180637A1 (es) 2002-07-30
ATE265448T1 (de) 2004-05-15
JP2003506447A (ja) 2003-02-18
NZ517087A (en) 2004-05-28
AU6895400A (en) 2001-03-05
CA2381621A1 (en) 2001-02-15
BR0013113A (pt) 2002-04-30
EP1208096A1 (en) 2002-05-29
AR025068A1 (es) 2002-11-06
EP1208096B1 (en) 2004-04-28
KR20020019969A (ko) 2002-03-13
ZA200200691B (en) 2003-10-29
NO20020569D0 (no) 2002-02-05
PE20010494A1 (es) 2001-06-27
CN1378543A (zh) 2002-11-06
WO2001010859A1 (en) 2001-02-15
DE60010280T2 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
IL193368A0 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
IL131273A0 (en) Phthalazines with angiogenesis inhibiting activity
IL147109A0 (en) Substtituted heterocycle fused gamma-carbolines
SG95616A1 (en) Stroller
JP2002544742A5 (enExample)
JP2003501666A5 (enExample)
HUP1300369A2 (enExample)
GB2363568B (en) Castor assemblies
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
GB0021915D0 (en) Creating and managing E-receipts
GB9913372D0 (en) Childs easy-brush
GB9922658D0 (en) Trolleys and castors for trolleys
GB2357242B (en) Castor
GB9903439D0 (en) Activity bib
TW404219U (en) Simplex tea set structure
TW394184U (en) Castor
GB0014826D0 (en) Perambulator
GB9921628D0 (en) Security cart
TW408724U (en) Cart structure
GB9925797D0 (en) Proximity Heater
TW401945U (en) Improved stroller structure
CA88412S (en) Stroller
GB9922029D0 (en) Castor and trolley fitted therewith
TW381456U (en) Multi-caliber flower arrangement structure capable of positive and reverse combination ato will
GB9914277D0 (en) Pushchairs and the like